Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 30, 2018

Evonetix raises £9 million for gene synthesis technology

Pioneering gene synthesis company Evonetix has completed a £9 million ($12.3 million) financing round to support the development of its scalable and high-fidelity gene synthesis technology.

By Charlotte Edwards

Pioneering gene synthesis company Evonetix has completed a £9 million ($12.3 million) financing round to support the development of its scalable and high-fidelity gene synthesis technology.

Cambridge-based Evonetix was founded in 2016 to develop technology that will enable the large-scale parallel synthesis of DNA on silicon arrays to meet the increasing demand for high-output and highly accurate DNA synthesis.

The financing was a series A round co-led by Silicon Valley investor DCVC and London-based Draper Esprit. Other investors supporting Evonetix are the Morningside group, alongside existing investors Providence Investment Company (Jersey), Cambridge Consultants (Cambridge, UK), Rising Tide Fund (San Francisco, CA) and Civilization Ventures (San Francisco, CA).

Artificial gene synthesis, also known as DNA synthesis, is a method used in synthetic biology to create genes in the laboratory. Evonetix claims the field of synthetic biology will be worth $40 billion in the early 2020s.

Synthetic biology is expected to have a significant impact across many industries and could be fundamental in helping to manage the Earth’s resources. If Evonetix manages to provide high-fidelity DNA at scale, without the need for post-synthesis error correction, the company could place itself in a powerful position in the synthetic biology market.

Matt Ocko, managing partner of DCVC, said: “This is a truly novel approach to gene synthesis that can deliver massive parallelisation with an extremely low error-rate for high-complexity RNA and DNA constructs. We are excited to back a team and technology that can materially reduce costs and improve innovation in our own portfolio companies and multiple global industries.”

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

Evonetix CEO Tim Brears said: “We are delighted to be supported by such high-quality investors who have a deep understanding of the requirements of synthetic biology and are committed to this important, emerging area of science, and we look forward to working with them through the next stage of the company’s development”.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU